Skip Navigation

Christopher Sweeney, MBBS


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Bladder cancer
  • Clinical trials
  • Hormone and chemotherapy
  • Kidney cancer
  • Prostate cancer
  • Testicular cancer

Contact Information

  • Appointments877-332-4294 (new)
    617-582-9725 (follow-up)
  • Office Phone Number617-632-1914
  • Fax617-632-2165

Board Certification:

  • Internal Medicine, 1997
  • Medical Oncology, 2000

Fellowship:

  • Indiana University, Hematology and Oncology

Residency:

  • Gundersen Lutheran Medical Center, Internal Medicine

Medical School:

  • University of Adelaide, Australia

Recent Awards:

  • Membership of the American Society of Clinical Oncology, Eastern Cooperative Oncology Group, and American Association for Cancer Research.
  • Chairman of the Hoosier Oncology Group 2005-2007
  • Program Committee and the Cancer Education Committee of the American Society of Clinical Oncology
  • Editorial Board, Journal of Clinical Oncology
  • Peer-reviewed funding from the National Institutes of Health and the Department of Defense, Lance Armstrong Foundation, and PhRMA.

Research

Preclinical drug development and drug evaluation, clinical trials in genitourinary malignancies (prostate, bladder, kidney, and testis cancer)

Dr. Sweeney has focused his academic career on the management of genitourinary malignancies, including prostate, bladder, testis, and renal cell cancer. His research interest has been primarily focused on drug development. This has included (i) design and conduct of phase I trials of new agents or new combinations that assess the safety and distribution of the drug in the body as well as the anti-cancer activity of the therapy; (ii) assessment of genetic variants and blood markers to try and define signatures that identify patients who are destined to benefit from a therapy; (iii) design and conduct of phase 2 and 3 clinical trials with a focus on bladder and prostate cancer and (iv) drug discovery and evaluation in the laboratory to guide clinical trial design.

McKay RR, Werner L, Jacobus SJ, Jones A, Mostaghel EA, Marck BT, Choudhury AD, Pomerantz MM, Sweeney CJ, Slovin SF, Morris MJ, Kantoff PW, Taplin ME. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2018 Nov 14.
View in: PubMed

Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ. Low Tristetraprolin Expression is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 Nov 12.
View in: PubMed

Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ. Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clin Genitourin Cancer. 2018 Oct 04.
View in: PubMed

Howard SA, Rosenthal MH, Qin L, Matalon SA, Bernard BD, Beard CJ, Sweeney CJ. Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors. Am J Clin Oncol. 2018 Oct; 41(10):949-952.
View in: PubMed

Tosco L, Briganti A, D'amico AV, Eastham J, Eisenberger M, Gleave M, Haustermans K, Logothetis CJ, Saad F, Sweeney C, Taplin ME, Fizazi K. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. Eur Urol. 2018 Oct 01.
View in: PubMed

Hamid AA, Markt SC, Vicier C, McDermott K, Richardson P, Ho VT, Sweeney CJ. Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clin Genitourin Cancer. 2018 Sep 19.
View in: PubMed

Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 Aug 14.
View in: PubMed

Sweeney CJ. Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next? Eur Urol. 2018 Oct; 74(4):420-421.
View in: PubMed

Reynolds PS, Fisher BJ, McCarter J, Sweeney C, Martin EJ, Middleton P, Ellenberg M, Fowler E, Brophy DF, Fowler AA, Spiess BD, Natarajan R. Interventional vitamin C: A strategy for attenuation of coagulopathy and inflammation in a swine multiple injuries model. J Trauma Acute Care Surg. 2018 Jul; 85(1S Suppl 2):S57-S67.
View in: PubMed

Morel KL, Ormsby RJ, Solly EL, Tran LNK, Sweeney CJ, Klebe S, Cordes N, Sykes PJ. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clin Exp Metastasis. 2018 Jun 23.
View in: PubMed

Choudhury AD, Gray KP, Supko JG, Harshman LC, Taplin ME, Pace AF, Farina M, Zukotynski KA, Bernard B, Kantoff PW, Pomerantz M, Sweeney C. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07.
View in: PubMed

Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest. 2018 Jul 02; 128(7):2979-2995.
View in: PubMed

Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Reply to J.J. Tao et al. J Clin Oncol. 2018 Aug 10; 36(23):2451.
View in: PubMed

Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Rydzewska LH, Sweeney CJ, Spears MR, Sydes MR, Tierney JF. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018 May 01; 29(5):1249-1257.
View in: PubMed

Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 May; 131(5):517-523.
View in: PubMed

Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol. 2018 Apr 10; 36(11):1088-1095.
View in: PubMed

Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018 06; 73(6):847-855.
View in: PubMed

Deraska PV, O'Leary C, Reavis HD, Labe S, Dinh TK, Lazaro JB, Sweeney C, D'Andrea AD, Kozono D. NF-?B inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. Cell Death Discov. 2018 Dec; 4:10.
View in: PubMed

Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 Apr 10; 36(11):1080-1087.
View in: PubMed

Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018 Feb 20; 36(6):536-542.
View in: PubMed

Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clin Genitourin Cancer. 2018 04; 16(2):130-134.
View in: PubMed

Xie W, Regan MM, Sweeney CJ. Reply to Y. Zhu et al. J Clin Oncol. 2018 Feb 10; 36(5):515-516.
View in: PubMed

McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer Prostatic Dis. 2018 09; 21(3):306-318.
View in: PubMed

Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 Feb 01; 36(4):376-382.
View in: PubMed

Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018 Mar; 25(3):220-231.
View in: PubMed

Harshman LC, Xie W, Moreira RB, Bossé D, Ruiz Ares GJ, Sweeney CJ, Choueiri TK. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. Cancer. 2018 Mar 01; 124(5):925-933.
View in: PubMed

Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018 Feb; 23(2):193-202.
View in: PubMed

Dorff TB, Sweeney CJ. Chemotherapy for oligometastatic prostate cancer. Curr Opin Urol. 2017 Nov; 27(6):553-558.
View in: PubMed

Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clin Cancer Res. 2017 Nov 15; 23(22):7072-7083.
View in: PubMed

Rowson-Hodel AR, Wald JH, Hatakeyama J, O'Neal WK, Stonebraker JR, VanderVorst K, Saldana MJ, Borowsky AD, Sweeney C, Carraway KL. Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene. 2018 01 11; 37(2):197-207.
View in: PubMed

Wong SE, North SA, Sweeney CJ, Stockler MR, Sridhar SS. Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clin Genitourin Cancer. 2017 Sep 08.
View in: PubMed

Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017 Sep 20; 35(27):3097-3104.
View in: PubMed

Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 10; 84:88-101.
View in: PubMed

Hamid AA, Sweeney CJ. Prostate cancer: A new standard-of-care for advanced-stage disease. Nat Rev Clin Oncol. 2017 Oct; 14(10):592-593.
View in: PubMed

O'Donnell E, Markt SC, Miller R, Bernard B, Albiges L, Beard C, Sweeney C. Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. Clin Genitourin Cancer. 2017 Aug 03.
View in: PubMed

Pezaro CJ, Omlin A, Mastris K, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Ann Oncol. 2017 08 01; 28(8):1692-1694.
View in: PubMed

Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, Nakabayashi M, McKay R, Pomerantz M, Mucci LA, Taplin ME, Sweeney CJ, Lee GM, Kantoff PW. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311.
View in: PubMed

Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, Allemani C. Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413]. Gynecol Oncol. 2017 12; 147(3):726.
View in: PubMed

Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C. Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404]. Gynecol Oncol. 2017 12; 147(3):725.
View in: PubMed

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211.
View in: PubMed

Wald JH, Hatakeyama J, Printsev I, Cuevas A, Fry WHD, Saldana MJ, VanderVorst K, Rowson-Hodel A, Angelastro JM, Sweeney C, Carraway KL. Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination. Oncogene. 2017 09 07; 36(36):5158-5167.
View in: PubMed

Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104.
View in: PubMed

Murphy DG, Sweeney CJ, Tombal B. "Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol. 2017 07; 72(1):1-3.
View in: PubMed

Morel KL, Ormsby RJ, Bezak E, Sweeney CJ, Sykes PJ. Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues In Vivo. Radiat Res. 2017 05; 187(5):501-512.
View in: PubMed

Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. Racial Disparities in Prostate Cancer Outcome among Prostate-Specific Antigen Screening Eligible Populations in the United States. Ann Oncol. 2017 Feb 08.
View in: PubMed

Bernard B, Muralidhar V, Chen YH, Sridhar SS, Mitchell EP, Pettaway CA, Carducci MA, Nguyen PL, Sweeney CJ. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 05 01; 123(9):1536-1544.
View in: PubMed

Clement JM, Sweeney CJ. Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer. J Oncol Pract. 2017 01; 13(1):9-18.
View in: PubMed

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat Rev. 2017 Feb; 53:79-97.
View in: PubMed

Briganti A, De Santis M, Giannarini G, Sweeney CJ. Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists. Eur Urol Focus. 2016 Dec; 2(5):463-464.
View in: PubMed

Sweeney C, Khalil L, Curry N. Transmission of severe haemophilia A by in vitro fertilization with donated eggs. Haemophilia. 2017 09; 23(5):e451-e453.
View in: PubMed

Taylor-Weiner A, Zack T, O'Donnell E, Guerriero JL, Bernard B, Reddy A, Han GC, AlDubayan S, Amin-Mansour A, Schumacher SE, Litchfield K, Turnbull C, Gabriel S, Beroukhim R, Getz G, Carter SL, Hirsch MS, Letai A, Sweeney C, Van Allen EM. Genomic evolution and chemoresistance in germ-cell tumours. Nature. 2016 11 30; 540(7631):114-118.
View in: PubMed

Lorente D, Fizazi K, Sweeney C, de Bono JS. Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. Eur Urol Focus. 2016 Dec; 2(5):488-498.
View in: PubMed

Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 2017 01; 18(1):132-142.
View in: PubMed

Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3.
View in: PubMed

Miller RE, Markt SC, O'Donnell E, Bernard B, Albiges LK, Beard C, Sweeney CJ. Age =40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. Eur Urol Focus. 2017 12; 3(6):621-628.
View in: PubMed

Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700.
View in: PubMed

Markt SC, Lago-Hernandez CA, Miller RE, Mahal BA, Bernard B, Albiges L, Frazier LA, Beard CJ, Wright AA, Sweeney CJ. Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer. 2016 Oct 15; 122(20):3127-3135.
View in: PubMed

Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, Komura K, Sweeney CJ, Sartor O, Lee GM, Kantoff PW. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clin Cancer Res. 2017 Feb 01; 23(3):726-734.
View in: PubMed

Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377.
View in: PubMed

Sadow CA, Maurer AN, Prevedello LM, Sweeney CJ, Silverman SG. CT restaging of testicular germ cell tumors: The incidence of isolated pelvic metastases. Eur J Radiol. 2016 Aug; 85(8):1439-44.
View in: PubMed

McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
View in: PubMed

Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW, Sweeney CJ. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci U S A. 2016 May 31; 113(22):6259-64.
View in: PubMed

Francini E, Sweeney CJ. Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 09; 70(3):410-2.
View in: PubMed

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2016 May 02.
View in: PubMed

Cejas P, Li L, O'Neill NK, Duarte M, Rao P, Bowden M, Zhou CW, Mendiola M, Burgos E, Feliu J, Moreno-Rubio J, Guadalajara H, Moreno V, García-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW. Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nat Med. 2016 06; 22(6):685-91.
View in: PubMed

Börnigen D, Tyekucheva S, Wang X, Rider JR, Lee GS, Mucci LA, Sweeney C, Huttenhower C. Computational Reconstruction of NF?B Pathway Interaction Mechanisms during Prostate Cancer. PLoS Comput Biol. 2016 Apr; 12(4):e1004820.
View in: PubMed

Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol. 2016 06 01; 34(16):1905-12.
View in: PubMed

McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol. 2016 06 01; 34(16):1913-20.
View in: PubMed

Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 Apr; 14(4):421-8.
View in: PubMed

Miller RE, Sweeney CJ. Chemotherapy for metastatic castrate-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2016 06; 19(2):139-44.
View in: PubMed

Rudman SM, Gray KP, Batista JL, Pitt MJ, Giovannucci EL, Harper PG, Loda M, Mucci LA, Sweeney CJ. Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU Int. 2016 Dec; 118(6):919-926.
View in: PubMed

Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Oncogene. 2016 Mar 03; 35(9):1206.
View in: PubMed

Zheng D, Gui B, Gray KP, Tinay I, Rafiei S, Huang Q, Sweeney CJ, Kibel AS, Jia L. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene. 2016 09 08; 35(36):4807-15.
View in: PubMed

Garcia JA, Sweeney C. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. N Engl J Med. 2016 01 21; 374(3):287.
View in: PubMed

Ko JJ, Bernard B, Tran B, Li H, Asif T, Stukalin I, Lee M, Day D, Alimohamed N, Sweeney CJ, Bedard PL, Heng DY. Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. J Clin Oncol. 2016 Mar 01; 34(7):714-20.
View in: PubMed

Bernard B, Gershman B, Karnes RJ, Sweeney CJ, Vapiwala N. Approach to Oligometastatic Prostate Cancer. Am Soc Clin Oncol Educ Book. 2016; 35:119-29.
View in: PubMed

Giannatempo P, Pond GR, Sonpavde G, Albany C, Loriot Y, Sweeney CJ, Salvioni R, Colecchia M, Nicolai N, Raggi D, Rice KR, Flack CK, El Mouallem NR, Feldman H, Fizazi K, Einhorn LH, Foster RS, Necchi A, Cary C. Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. J Urol. 2016 07; 196(1):95-100.
View in: PubMed

Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Sweeney CJ, Sydes MR, Tombal B, Tierney JF. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016 Feb; 17(2):243-256.
View in: PubMed

Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
View in: PubMed

Sridhar SS, Sweeney CJ. It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer. Eur Urol. 2016 08; 70(2):263-4.
View in: PubMed

Kryukov GV, Bielski CM, Samocha K, Fromer M, Seepo S, Gentry C, Neale B, Garraway LA, Sweeney CJ, Taplin ME, Van Allen EM. Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clin Cancer Res. 2016 05 01; 22(9):2183-9.
View in: PubMed

Sweeney CJ. The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation Therapy. JAMA Oncol. 2015 Dec; 1(9):1270-1.
View in: PubMed

Bernard B, Sweeney CJ. Diagnosis and Treatment of Testicular Cancer: A Clinician's Perspective. Surg Pathol Clin. 2015 Dec; 8(4):717-23.
View in: PubMed

Nezolosky MD, Dinh KT, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016 Feb; 34(2):57.e15-22.
View in: PubMed

Lu D, Sinnott JA, Valdimarsdóttir U, Fang F, Gerke T, Tyekucheva S, Fiorentino M, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, Mucci LA, Fall K. Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clin Cancer Res. 2016 Feb 01; 22(3):765-772.
View in: PubMed

Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A, Boyle H, Chung P, Huddart RA, Bokemeyer C, Tryakin A, Sava T, Winquist EW, De Giorgi U, Aparicio J, Sweeney CJ, Cohn Cedermark G, Beyer J, Powles T. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. J Clin Oncol. 2016 Feb 01; 34(4):345-51.
View in: PubMed

Sweeney C, Nakabayashi M, Regan M, Xie W, Hayes J, Keating N, Li S, Philipson T, Buyse M, Halabi S, Kantoff P, Sartor AO, Soule H, Mahal B. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst. 2015 Dec; 107(12):djv261.
View in: PubMed

Sharmeen F, Rosenthal MH, Wood MJ, Tirumani SH, Sweeney C, Howard SA. Relationship Between the Pathologic Subtype/Initial Stage and Microliths in Testicular Germ Cell Tumors. J Ultrasound Med. 2015 Nov; 34(11):1977-82.
View in: PubMed

Dinh KT, Muralidhar V, Mahal BA, Chen YW, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Occult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32.
View in: PubMed

Yokdang N, Hatakeyama J, Wald JH, Simion C, Tellez JD, Chang DZ, Swamynathan MM, Chen M, Murphy WJ, Carraway Iii KL, Sweeney C. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells. Oncogene. 2016 06 02; 35(22):2932-47.
View in: PubMed

Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng FY, Martin NE, Efstathiou JA, Choueiri TK, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85.
View in: PubMed

Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF, Thornton CM, Arul GS, Stoneham SJ, Pashankar F, Stark D, Shaikh F, Gershenson DM, Covens A, Hurteau J, Stenning SP, Feldman DR, Grimison PS, Huddart RA, Sweeney C, Powles T, Lopes LF, dos Santos Agular S, Chinnaswamy G, Khaleel S, Abouelnaga S, Hale JP, Frazier AL. Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. J Clin Oncol. 2015 Sep 20; 33(27):3018-28.
View in: PubMed

Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Trinh QD, Nguyen PL. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int. 2016 Jul; 118(1):95-101.
View in: PubMed

Wang X, Huang Y, Christie A, Bowden M, Lee GS, Kantoff PW, Sweeney CJ. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity. Clin Cancer Res. 2015 Dec 15; 21(24):5578-87.
View in: PubMed

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20; 373(8):737-46.
View in: PubMed

Wood MJ, Tirumani SH, Sweeney C, Ramaiya NH, Howard SA. Approach to risk stratification in testicular germ cell tumors: a primer for radiologists. Abdom Imaging. 2015 Aug; 40(6):1871-86.
View in: PubMed

Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):828-35.
View in: PubMed

Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Oncogene. 2016 Mar 03; 35(9):1143-52.
View in: PubMed

Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M, Lee GS, Kantoff PW. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncol. 2015 Jul; 1(4):495-504.
View in: PubMed

Muralidhar V, Ziehr DR, Mahal BA, Chen YW, Nezolosky MD, Viswanathan VB, Choueiri TK, Sweeney CJ, Trinh QD, Nguyen PL. Association Between Older Age and Increasing Gleason Score. Clin Genitourin Cancer. 2015 Dec; 13(6):525-30.e1-3.
View in: PubMed

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015 Aug; 26(8):1589-604.
View in: PubMed

McCall KC, Cheng SC, Huang Y, Kohl NE, Tupper T, Van den Abbeele AD, Zukotynski KA, Sweeney CJ. [(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. Transl Oncol. 2015 Jun; 8(3):147-53.
View in: PubMed

Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8.
View in: PubMed

Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015 Jul; 33(7):330.e19-25.
View in: PubMed

Lago-Hernandez CA, Feldman H, O'Donnell E, Mahal BA, Perez V, Howard S, Rosenthal M, Cheng SC, Nguyen PL, Beard C, D'Amico AV, Sweeney CJ. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann Oncol. 2015 Jul; 26(7):1396-401.
View in: PubMed

Börnigen D, Moon YS, Rahnavard G, Waldron L, McIver L, Shafquat A, Franzosa EA, Miropolsky L, Sweeney C, Morgan XC, Garrett WS, Huttenhower C. A reproducible approach to high-throughput biological data acquisition and integration. PeerJ. 2015; 3:e791.
View in: PubMed

Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015 May 15; 75(10):1944-8.
View in: PubMed

Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske A, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson T. A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2015 Aug 01; 21(15):3420-7.
View in: PubMed

Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015 Jun; 26(6):1230-7.
View in: PubMed

Valenca LB, Sweeney CJ, Pomerantz MM. Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treat Rev. 2015 Apr; 41(4):332-40.
View in: PubMed

Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 Jun 15; 75(9):897-906.
View in: PubMed

Bernard B, Sweeney CJ. Management of metastatic hormone-sensitive prostate cancer. Curr Urol Rep. 2015 Mar; 16(3):14.
View in: PubMed

Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9.
View in: PubMed

Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16.
View in: PubMed

Nakshatri H, Appaiah HN, Anjanappa M, Gilley D, Tanaka H, Badve S, Crooks PA, Mathews W, Sweeney C, Bhat-Nakshatri P. NF-?B-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. Cell Death Dis. 2015 Jan 22; 6:e1608.
View in: PubMed

Sweeney CJ, Chamberlain D. Insights into E3805: the CHAARTED trial. Future Oncol. 2015; 11(6):897-9.
View in: PubMed

Zukotynski KA, Kim CK, Gerbaudo VH, Hainer J, Taplin ME, Kantoff P, den Abbeele AD, Seltzer S, Sweeney CJ. (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging. 2015; 5(1):72-82.
View in: PubMed

Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52.
View in: PubMed

Voskoboynik M, Staffurth J, Malik Z, Sweeney C, Chowdhury S. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Rev Anticancer Ther. 2014 Nov; 14(11):1253-6.
View in: PubMed

Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65.
View in: PubMed

Ziehr DR, Mahal BA, Aizer AA, Hyatt AS, Beard CJ, D Amico AV, Choueiri TK, Elfiky A, Lathan CS, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13.
View in: PubMed

Howard SA, Gray KP, O'Donnell EK, Fennessy FM, Beard CJ, Sweeney CJ. Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. AJR Am J Roentgenol. 2014 Oct; 203(4):W415-20.
View in: PubMed

Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20; 32(30):3391-9.
View in: PubMed

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Lago-Hernandez C, Chen YW, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Trinh QD, Nguyen PL. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9.
View in: PubMed

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014 Aug; 84(2):386-92.
View in: PubMed

Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL. Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8.
View in: PubMed

Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Lathan C, Kim SP, Trinh QD, Nguyen PL. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014 Nov; 32(8):1285-91.
View in: PubMed

Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
View in: PubMed

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e189-95.
View in: PubMed

Hsieh CL, Fei T, Chen Y, Li T, Gao Y, Wang X, Sun T, Sweeney CJ, Lee GS, Chen S, Balk SP, Liu XS, Brown M, Kantoff PW. Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7319-24.
View in: PubMed

Seible DM, Gu X, Hyatt AS, Beard CJ, Choueiri TK, Efstathiou JA, Miyamoto DT, Mitin T, Martin NE, Sweeney CJ, Trinh QD, Beckman JA, Basaria S, Nguyen PL. Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun; 83(6):1316-21.
View in: PubMed

Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
View in: PubMed

Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ. Elevated IL-8, TNF-a, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014 Jun; 74(8):820-8.
View in: PubMed

Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015 Feb; 67(2):310-8.
View in: PubMed

Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRa) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar; 73(3):595-604.
View in: PubMed

Sweeney CJ. Preface. Prostate cancer. Hematol Oncol Clin North Am. 2013 Dec; 27(6):xi-xii.
View in: PubMed

Ravi P, Gray KP, O'Donnell EK, Sweeney CJ. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. Ann Oncol. 2014 Feb; 25(2):331-8.
View in: PubMed

Kaymakcalan M, Stuver S, Sweeney C, Jacobson JO, Weingart S. Developing and promoting evidence-based use of granulocyte colony stimulating factors (GCSF) in the palliative chemotherapy setting. J Clin Oncol. 2013 Nov; 31(31_suppl):172.
View in: PubMed

Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014 Feb; 74(3):225-34.
View in: PubMed

Hahn NM, Yiannoutsos CT, Kirkpatrick K, Sharma J, Sweeney CJ. Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event. Clin Genitourin Cancer. 2014 Feb; 12(1):33-40.e4.
View in: PubMed

Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, Jewett M, Warde P, Sweeney CJ, Beard C, Powles T, Tyldesley S, So A, Porter C, Olgac S, Fizazi K, Hayes-Lattin B, Grimison P, Toner G, Cathomas R, Bokemeyer C, Kollmannsberger C. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol. 2013 Oct 01; 31(28):3490-3.
View in: PubMed

Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, Balk S, Lee GS, Kantoff PW. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2014 May 22; 33(21):2790-800.
View in: PubMed

Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer. 2013 Aug 15; 119(16):2990-8.
View in: PubMed

Dang LH, Lauer RC, Starodub A, Hauke RJ, Galsky MD, Bylow KA, Cowey CL, Bibby DC, Kremmidiotis G, Doolin EE, Lavranos TC, Sonpavde G, Logan T, Hahn NM, Sweeney C, Sarantopoulos J. Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):397.
View in: PubMed

Dittrich C, Duran Martinez I, Jagdev S, Millard FE, Sweeney C, Bajorin DF, Cerbone L, Dunn RM, Sen P, Shi M, Kay AC, Squires M, Sternberg CN. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. J Clin Oncol. 2013 Feb 20; 31(6_suppl):255.
View in: PubMed

Jacobus SJ, Qu AQ, Sweeney C, Appleman LJ, Tretter CP, Bubley GJ, Elfiky A, Park R, Stack EC, Signoretti S, Walsh MK, Steele G, Hirsch MS, Krajewski KM, Taplin ME, Rosenberg JE, Ross RW. A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. J Clin Oncol. 2013 Feb 20; 31(6_suppl):278.
View in: PubMed

Gray KP, Ravi P, Sweeney C. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT). J Clin Oncol. 2013 Feb 20; 31(6_suppl):324.
View in: PubMed

Gray KP, Nakabayashi M, Evan C, O'Donnell E, Pomerantz M, Kantoff PW, Sweeney C. Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. J Clin Oncol. 2013 Feb 20; 31(6_suppl):33.
View in: PubMed

Gray KP, Hirsch MS, Ravi P, Beard C, Sweeney C. A 10-year retrospective review of germ cell tumors not cured with cisplatin-based chemotherapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):325.
View in: PubMed

Sweeney C. Prostate cancer therapy: going forwards by going backwards. Lancet Oncol. 2013 Feb; 14(2):104-5.
View in: PubMed

Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9.
View in: PubMed

Valencia PM, Pridgen EM, Perea B, Gadde S, Sweeney C, Kantoff PW, Bander NH, Lippard SJ, Langer R, Karnik R, Farokhzad OC. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond). 2013 May; 8(5):687-98.
View in: PubMed

Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
View in: PubMed

Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012 Apr 04; 4(128):128ra39.
View in: PubMed

Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fosså SD, Travis LB, Beard CJ. Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):383-9.
View in: PubMed

Rudman SM, Gray KP, Kasperzyk J, Pitt M, Giovannucci E, Loda M, Mucci L, Sweeney C. Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):56.
View in: PubMed

Sharma J, Gray KP, Nakabayashi M, Petrozziello G, Evan C, Fichorova R, Kantoff PW, Sweeney C. Use of elevated baseline IL-8, CCL-2, and TNFa to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT). J Clin Oncol. 2012 Feb 10; 30(5_suppl):13.
View in: PubMed

Hutson TE, Dang LH, Lauer RC, Starodub A, Hauke RJ, Logan T, Bylow KA, Galsky MD, Bibby DC, Kremmidiotis G, Doolin EE, Lavranos TC, Leske AF, Hahn NM, Sonpavde G, Sweeney C, Sarantopoulos J. Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group). J Clin Oncol. 2012 Feb 10; 30(5_suppl):373.
View in: PubMed

Sharma J, Gray KP, Nakabayashi M, Petrozziello G, Evan C, Fichorova R, Kantoff PW, Sweeney C. Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT). J Clin Oncol. 2012 Feb 10; 30(5_suppl):191.
View in: PubMed

Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom ST, McConkey DJ, Palladino MA, Spear MA. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012 Dec; 30(6):2303-17.
View in: PubMed

Estabrook NC, Chin-Sinex H, Borgmann AJ, Dhaemers RM, Shapiro RH, Gilley D, Huda N, Crooks P, Sweeney C, Mendonca MS. Inhibition of NF-?B and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays. Free Radic Biol Med. 2011 Dec 15; 51(12):2249-58.
View in: PubMed

Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011 Sep; 186(3):865-72.
View in: PubMed

Patel YR, Carr KA, Magjuka D, Mohammadi Y, Dropcho EF, Reed AD, Moore ML, Waddell MJ, Shedd-Steele R, Sweeney CJ, Hahn NM. Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: implications for future genomic research in minority populations. Cancer. 2012 Feb 15; 118(4):1075-82.
View in: PubMed

Sharma J, Yiannoutsos CT, Hahn NM, Sweeney C. Prognositic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4594.
View in: PubMed

Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, Haas NB, Harzstark AL, Kurzrock R, Lara P, Lin C, Sella A, Small EJ, Spira AI, Vaishampayan UN, Vogelzang NJ, Scheffold C, Ballinger MD, Schimmoller F, Smith DC. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol. 2011 May 20; 29(15_suppl):4516.
View in: PubMed

Hutson TE, Sarantopoulos J, Logan T, Sonpavde G, Galsky MD, Sweeney C, Bibby DC, Kremmidiotis G, Doolin EE, Hahn NM. Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors. J Clin Oncol. 2011 May 20; 29(15_suppl):TPS194.
View in: PubMed

Hahn NM, Jung J, Dantzer J, Philips S, Patel YR, Carr KA, Mohammadi Y, Magjuka D, Camp C, Bolden M, Dropcho EF, Knight JA, Moore ML, Reed AD, Waddell MJ, Klaunig JE, Li L, Sweeney C, Skaar TC. A case-control study examining associations of germ-line oxidative DNA repair single-nucleotide polymorphisms (SNPs) with lethal prostate cancer (PCa) risk. J Clin Oncol. 2011 May 20; 29(15_suppl):4645.
View in: PubMed

Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, Sweeney CJ. A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-?B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10):2481-94.
View in: PubMed

Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011 Apr 20; 29(12):1525-30.
View in: PubMed

Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res. 2011 Jan 15; 17(2):363-71.
View in: PubMed

Guancial EA, Rosenberg JE, Sweeney CJ. Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy. Am Soc Clin Oncol Educ Book. 2011; 2011:171-176.
View in: PubMed

Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov H, Pollack A, Dicker A, Sandler H, Sweeney CJ. Evaluation of nuclear factor ?B and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int. 2011 Jul; 108(2 Pt 2):E51-8.
View in: PubMed

Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DS, Galbraith S. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol. 2011 Jun; 22(6):1413-9.
View in: PubMed

Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010 Dec 01; 304(21):2373-80.
View in: PubMed

Heath EI, Chiorean EG, Sweeney CJ, Hodge JP, Lager JJ, Forman K, Malburg L, Arumugham T, Dar MM, Suttle AB, Gainer SD, LoRusso P. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Dec; 88(6):818-23.
View in: PubMed

Flanagan J, Gray PK, Hahn N, Hayes J, Myers LJ, Carney-Doebbeling C, Sweeney CJ. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol. 2011 Apr; 22(4):801-7.
View in: PubMed

Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol. 2010 Oct 10; 28(29):4513-20.
View in: PubMed

O'Brien M, Lonergan R, Costelloe L, O'Rourke K, Fletcher JM, Kinsella K, Sweeney C, Antonelli G, Mills KH, O'Farrelly C, Hutchinson M, Tubridy N. OAS1: a multiple sclerosis susceptibility gene that influences disease severity. Neurology. 2010 Aug 03; 75(5):411-8.
View in: PubMed

Shamash J, Stebbing J, Sweeney C, Sonpavde G, Harland S, Dawkins G, Brock C, Abelman W, Wilson P, Sanitt A, Oliver T, Powles T. A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer. 2010 Aug 01; 116(15):3595-602.
View in: PubMed

Shanmugam R, Kusumanchi P, Cheng L, Crooks P, Neelakantan S, Matthews W, Nakshatri H, Sweeney CJ. A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. Prostate. 2010 Jul 01; 70(10):1074-86.
View in: PubMed

Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011 Dec; 29(6):1465-74.
View in: PubMed

Resta LP, Pili R, Eisenberger MA, Spitz A, King S, Porter J, Franke A, Boinpally R, Carducci MA, Sweeney CJ. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemother Pharmacol. 2011 Feb; 67(2):431-8.
View in: PubMed

Rosen PJ, Sweeney CJ, Park DJ, Beaupre DM, Deng H, Leitch IM, Shubhakar P, Zhu M, Oliner KS, Anderson A, Yee LK. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res. 2010 May 01; 16(9):2677-87.
View in: PubMed

Chiorean EG, Malireddy S, Younger AE, Jones DR, Waddell MJ, Sloop MI, Yu M, Hall SD, Schneider B, Sweeney CJ. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010 Aug; 66(3):441-8.
View in: PubMed

Sweeney CJ, Takimoto C, Wood L, Porter JM, Tracewell WG, Darwish M, D'Andrea DM, Remick SC. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol. 2010 Jul; 66(2):345-56.
View in: PubMed

Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, Whalen C, Shanmugam R, Skaar T, Sweeney CJ. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol. 2009 Dec; 20(12):1971-6.
View in: PubMed

Hahn NM, Stadler WM, Zon RT, Waterhouse DM, Picus J, Nattam SR, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ. A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475. J Clin Oncol. 2009 May 20; 27(15_suppl):5018.
View in: PubMed

Clarke SJ, Smith JT, Gebbie C, Sweeney C, Olszewski N. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):3025.
View in: PubMed

Gardiner RA, Sweeney C, Tilley WD. Testosterone therapy in castrate-resistant prostate cancer: a possible new approach. Eur Urol. 2009 Aug; 56(2):245-6.
View in: PubMed

Watson C, Miller DA, Chin-Sinex H, Losch A, Hughes W, Sweeney C, Mendonca MS. Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells. Radiat Res. 2009 Apr; 171(4):389-96.
View in: PubMed

Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol. 2009 Jan 20; 27(3):460-3.
View in: PubMed

Yip-Schneider MT, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks PA, Neelakantan S, Sweeney CJ, Schmidt CM. Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas. 2008 Oct; 37(3):e45-53.
View in: PubMed

Strother RM, Sweeney C. Lessons learned from development of docetaxel. Expert Opin Drug Metab Toxicol. 2008 Jul; 4(7):1007-19.
View in: PubMed

Carpenter JS, Rawl S, Porter J, Schmidt K, Tornatta J, Ojewole F, Helft P, Potter DA, Sweeney C, Giesler RB. Oncology outpatient and provider responses to a computerized symptom assessment system. Oncol Nurs Forum. 2008 Jul; 35(4):661-9.
View in: PubMed

Stutz MA, Shattuck DL, Laederich MB, Carraway KL, Sweeney C. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene. 2008 Sep 25; 27(43):5741-52.
View in: PubMed

Bahleda R, Felip E, Herbst RS, Hanna NH, Laurie SA, Shepherd FA, Armand JP, Sweeney CJ, Calvo-Aller E, Soria JC. Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):2564.
View in: PubMed

Strother RM, Jones D, Li L, Younger A, Einhorn LH, Williams S, Sweeney CJ. Effect of the C3435T genetic polymorphism in MDR1 on etoposide pharmacokinetics. J Clin Oncol. 2008 May 20; 26(15_suppl):2500.
View in: PubMed

Hahn NM, Zon RT, Jones T, Ademuyiwa F, Dugan WM, Whalen C, Yu M, Shanmugam R, Skaar T, Sweeney CJ. A multicenter phase II study of pemetrexed as second-line chemotherapy for the treatment of hormone refractory prostate cancer (HRPC); Hoosier Oncology Group GU-0367. J Clin Oncol. 2008 May 20; 26(15_suppl):16019.
View in: PubMed

Sweeney CJ, Chriorean EG, Mita MM, Papadopoulos KP, Silver B, Freed M, Gokemeijer J, Eaton C, Furfine E, Tolcher AW. Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST). J Clin Oncol. 2008 May 20; 26(15_suppl):3523.
View in: PubMed

Youssoufian H, Amato RJ, Sweeney CJ, Chiorean EG, Fox F, Katz T, Rowinsky EK. Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFRa in patients with advanced solid malignancies. J Clin Oncol. 2008 May 20; 26(15_suppl):14617.
View in: PubMed

Rosen PJ, Sweeney CJ, Park DJ, Rasmussen E, Shubhakar P, Scripture C, Leitch I, Lu J, Beaupre DM, Yee LK. AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):3570.
View in: PubMed

Chiorean EG, Sweeney CJ, Verschraegen CF, Lee FC, Jones SF, Rabinowitz I, Tye L, Bello A, Chao R, Burris HA. Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): A phase I dose-finding study. J Clin Oncol. 2008 May 20; 26(15_suppl):3562.
View in: PubMed

Harrison MR, Hahn N, Pili R, Oh WK, Kim K, Wilding G, Sweeney CJ, Sidor C, Arnott J, Liu G. Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5173.
View in: PubMed

Malireddy SR, Chiorean EG, Younger A, Jones D, Waddell M, Margol M, Hall S, Schneider BP, Sweeney CJ. A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis. J Clin Oncol. 2008 May 20; 26(15_suppl):14521.
View in: PubMed

Schwertschlag US, Chiorean EG, Anthony SP, Sweeney CJ, Borad MJ, Von Hoff DD, Garlich JR, Shelton CF, Ramanathan RK. Phase 1 pharmacokinetic (PK) and pharmacodynamic(PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3- kinase (PI3K) inhibitor in patients with solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):14532.
View in: PubMed

Chiorean EG, Porter JM, Foster AE, Al Omari AS, Yoder CA, Fife KL, Strother RM, Murry DJ, Yu M, Jones DR, Sweeney CJ. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin Cancer Res. 2008 Feb 15; 14(4):1131-7.
View in: PubMed

Li L, Yu M, Jason RD, Shen C, Azzouz F, McLeod HL, Borges-Gonzales S, Nguyen A, Skaar T, Desta Z, Sweeney CJ, Flockhart DA. A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. J Biopharm Stat. 2008; 18(6):1150-77.
View in: PubMed

Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR, Kadmon D. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 2007 Dec 15; 110(12):2628-39.
View in: PubMed

Mendonca MS, Chin-Sinex H, Gomez-Millan J, Datzman N, Hardacre M, Comerford K, Nakshatri H, Nye M, Benjamin L, Mehta S, Patino F, Sweeney C. Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair. Radiat Res. 2007 Dec; 168(6):689-97.
View in: PubMed

Hahn NM, Kelley MR, Klaunig JE, Koch MO, Li L, Sweeney CJ. Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implications. Future Oncol. 2007 Dec; 3(6):665-82.
View in: PubMed

Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP, Sternberg CN. Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int. 2008 Apr; 101(8):937-43.
View in: PubMed

Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007 Dec 15; 110(13):4427-35.
View in: PubMed

Vegeler RC, Yip-Schneider MT, Ralstin M, Wu H, Crooks PA, Neelakantan S, Nakshatri H, Sweeney CJ, Schmidt CM. Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer. J Surg Res. 2007 Nov; 143(1):169-76.
View in: PubMed

Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther. 2007 Jun; 6(6):1736-44.
View in: PubMed

Kyselova Z, Mechref Y, Al Bataineh MM, Dobrolecki LE, Hickey RJ, Vinson J, Sweeney CJ, Novotny MV. Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res. 2007 May; 6(5):1822-32.
View in: PubMed

Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20; 25(6):675-81.
View in: PubMed

Sweeney C. The case for systemic therapy alone for prostate cancer. J Urol. 2006 Dec; 176(6 Pt 2):S42-6.
View in: PubMed

Masters AR, Sweeney CJ, Jones DR. The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 01; 848(2):379-83.
View in: PubMed

Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):6094-9.
View in: PubMed

Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW, Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ. Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate. 2006 Oct 01; 66(14):1498-511.
View in: PubMed

Sweeney CJ. ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin Adv Hematol Oncol. 2006 Aug; 4(8):588-90.
View in: PubMed

Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006 Jul 20; 24(21):3451-7.
View in: PubMed

Vaughn DJ, Powell M, Catalano PJ, Loehrer P, Nichols C, Sweeney C, Wilding G, Dipaola RS. The influence of body mass index (BMI) on outcome in patients with advanced germ cell tumors (GCT). J Clin Oncol. 2006 Jun 20; 24(18_suppl):14594.
View in: PubMed

Strother RM, Jones DR, Skaar T, Huh WS, Porter J, Foster A, Sweeney C. Erlotinib-associated rash correlates with plasma levels at steady state. J Clin Oncol. 2006 Jun 20; 24(18_suppl):13008.
View in: PubMed

Bernstein ED, Bae K, Baldridge LA, Zhang S, Cheng L, Wolkov H, Pilepich M, Dicker AP, Sweeney CJ. Looking for new targets for prostate cancer therapy: Nuclear factor kappa B and CXCR4 co-expression in prostate specimens from RTOG-8610. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14578.
View in: PubMed

Flanagan JR, Carney-Doebbeling C, Jones L, Sweeney C. Metabolic syndrome predicts for shorter response to hormonal therapy in prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4554.
View in: PubMed

Rosen LS, Wilding G, Sweeney C, Casale D, Kollia G, Wu C, Ayers M, Hill C, Galbraith SM. Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):3051.
View in: PubMed

Hahn NM, Whalen C, Sweeney CJ. Second-line pemetrexed (P) for the treatment of hormone refractory prostate cancer (HRPC): A Hoosier Oncology Group phase II study-Preliminary analysis. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4644.
View in: PubMed

Schneider B, Fukunaga A, Murry D, Yoder C, Fife K, Foster A, Rosenberg L, Kelich S, Li L, Sweeney C. A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors. Cancer Chemother Pharmacol. 2007 Feb; 59(2):261-8.
View in: PubMed

Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1966-9.
View in: PubMed

Sweeney CJ, Takimoto CH, Latz JE, Baker SD, Murry DJ, Krull JH, Fife K, Battiato L, Cleverly A, Chaudhary AK, Chaudhuri T, Sandler A, Mita AC, Rowinsky EK. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Clin Cancer Res. 2006 Jan 15; 12(2):536-42.
View in: PubMed

Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006 Feb 01; 24(4):552-62.
View in: PubMed

Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6625-33.
View in: PubMed

Pan CX, Loehrer P, Seitz D, Helft P, Juliar B, Ansari R, Pletcher W, Vinson J, Cheng L, Sweeney C. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology. 2005; 69(1):63-70.
View in: PubMed

Hahn NM, Sweeney CJ. Germ cell tumors: an update of recent data and review of active protocols in stage I and metastatic disease. Urol Oncol. 2005 Jul-Aug; 23(4):293-302.
View in: PubMed

Agus DB, Sweeney CJ, Morris M, Mendelson D, McNeel DG, Ahmann F, Wang J, Derynck MK, Kattan MW, Scher HI. Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy. J Clin Oncol. 2005 Jun; 23(16_suppl):4624.
View in: PubMed

Hahn NM, Fisher W, Langdon R, Zon R, Mark B, Sweeney CJ. A multicenter randomized phase II study of docetaxel (D) plus vinorelbine (VRB) and docetaxel plus estramustine (EMP) in combination for the treatment of hormone refractory prostate cancer (HRPC): HOG GU-0009. J Clin Oncol. 2005 Jun; 23(16_suppl):4568.
View in: PubMed

Kaufman HL, Wang W, Manola J, Dipaola RS, Ko YJ, Sweeney CJ, Whiteside T, Schlom J, Wilding G, Weiner LM. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: Follow-up clinical results from ECOG 7897. J Clin Oncol. 2005 Jun; 23(16_suppl):4501.
View in: PubMed

Sweeney CJ, Mehrotra S, Sadaria MR, Kumar S, Shortle NH, Roman Y, Sheridan C, Campbell RA, Murry DJ, Badve S, Nakshatri H. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther. 2005 Jun; 4(6):1004-12.
View in: PubMed

Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther. 2005 Apr; 4(4):587-94.
View in: PubMed

Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, Einhorn LH, Sweeney CJ. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol. 2005 Feb 20; 23(6):1185-91.
View in: PubMed

Miller KD, Sweeney CJ, Sledge GW. Can tumor angiogenesis be inhibited without resistance? EXS. 2005; (94):95-112.
View in: PubMed

Slattery ML, Samowtiz W, Ma K, Murtaugh M, Sweeney C, Levin TR, Neuhausen S. CYP1A1, cigarette smoking, and colon and rectal cancer. Am J Epidemiol. 2004 Nov 01; 160(9):842-52.
View in: PubMed

Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res. 2004 Aug 15; 10(16):5501-7.
View in: PubMed

Curry EA, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, O'Connell M, Sweeney CJ. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs. 2004 Aug; 22(3):299-305.
View in: PubMed

Takimoto CH, Saif MW, Lorusso PM, Sweeney C, Ducharme MP, Chu SQ, Schwartz GH, Danna M, De Jager RL, Rowinsky EK. A pharmacokinetic (PK) dose escalation study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: A comparison of the NCI hepatic dysfunction criteria and the Child-Pugh classification. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2017.
View in: PubMed

Sweeney CJ, Saif MW, Lorusso PM, Ducharme MP, Demnati R, Danna M, Rowinsky E, Mita M, Dejager R, Takimoto C. A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2069.
View in: PubMed

Remick S, Sweeney C, Takimoto C, Douer D, Bernareggi A. Pharmacokinetics (PK) of arsenic trioxide in cancer patients (pts) with renal dysfunction: Preliminary results. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2018.
View in: PubMed

Porter J, Murry D, Dropcho S, Seitz D, Helft P, Yoder C, Fife K, Sweeney CJ. A dose escalation and pharmacokinetic (PK) trial of weekly docetaxel combined with daily erlotinib in adult cancer patients. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2119.
View in: PubMed

Shafqat A, Titzer ML, Sweeney CJ, Giesler RB, Hanna A, Porter J, Selbe K, Daggy J, Einhorn LH. A phase II study of venlafaxine for the treatment of hot flashes in men undergoing androgen deprivation for prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8148.
View in: PubMed

Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, Eble JN. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res. 2004 Jul-Aug; 24(4):2135-40.
View in: PubMed

Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004 Jun 01; 22(11):2122-32.
View in: PubMed

Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, Chaudhary A, Fife K, Battiato L, Sweeney C, Jordan C, Burgess M, Slapak CA. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res. 2004 May 15; 10(10):3265-72.
View in: PubMed

Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S, Baldridge LA, Jones TD, Koch MO, Ulbright TM, Eble JN, Cheng L. PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin Cancer Res. 2004 Feb 15; 10(4):1333-7.
View in: PubMed

Sweeney C, Carraway KL. Negative regulation of ErbB family receptor tyrosine kinases. Br J Cancer. 2004 Jan 26; 90(2):289-93.
View in: PubMed

Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int. 2004 Jan; 93(1):143-50.
View in: PubMed

Paterson RF, Ulbright TM, MacLennan GT, Zhang S, Pan CX, Sweeney CJ, Moore CR, Foster RS, Koch MO, Eble JN, Cheng L. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer. 2003 Nov 01; 98(9):1830-6.
View in: PubMed

Brandli DW, Ulbright TM, Foster RS, Cummings OW, Zhang S, Sweeney CJ, Eble JN, Cheng L. Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Res. 2003 Sep 15; 63(18):6063-8.
View in: PubMed

Sweeney CJ. Why cyclooxygenase-2 inhibition plus chemotherapy? Am J Clin Oncol. 2003 Aug; 26(4):S122-5.
View in: PubMed

Madani A, Kemmer K, Sweeney C, Corless C, Ulbright T, Heinrich M, Einhorn L. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol. 2003 Jun; 14(6):873-80.
View in: PubMed

Hanna N, Sweeney C, Fife K, Dropcho S, Seitz DE. Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors. Am J Clin Oncol. 2003 Apr; 26(2):200-2.
View in: PubMed

Sweeney CJ, Miller KD, Sledge GW. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med. 2003 Jan; 9(1):24-9.
View in: PubMed

Miller KD, Sweeney CJ, Sledge GW. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol. 2003 Jan; 14(1):20-8.
View in: PubMed

Sanchez KM, Sweeney CJ, Mass R, Koch MO, Eckert GJ, Geary WA, Baldridge LA, Zhang S, Eble JN, Cheng L. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. Cancer. 2002 Oct 15; 95(8):1650-5.
View in: PubMed

Zhang S, Zeng G, Kao C, Gardner T, Sweeney C, Yang NS, Eble JN, Cheng L. Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. Prostate. 2002 Sep 15; 53(1):69-76.
View in: PubMed

Curry EA, Sweeney CJ. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer. J Urol. 2002 Jul; 168(1):193.
View in: PubMed

Seo YR, Sweeney C, Smith ML. Selenomethionine induction of DNA repair response in human fibroblasts. Oncogene. 2002 May 23; 21(23):3663-9.
View in: PubMed

Bhat-Nakshatri P, Sweeney CJ, Nakshatri H. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene. 2002 Mar 27; 21(13):2066-78.
View in: PubMed

Sweeney CJ, Monaco FJ, Jung SH, Wasielewski MJ, Picus J, Ansari RH, Dugan WM, Einhorn LH. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol. 2002 Mar; 13(3):435-40.
View in: PubMed

Cheng L, Gu J, Ulbright TM, MacLennan GT, Sweeney CJ, Zhang S, Sanchez K, Koch MO, Eble JN. Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer. 2002 Jan 01; 94(1):104-10.
View in: PubMed

Sweeney CJ, Marshall MS, Barnard DS, Heilman DK, Billings SD, Cheng L, Marshall SJ, Yip-Schneider MT. Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detect Prev. 2002; 26(3):238-44.
View in: PubMed

Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma . Cancer. 2001 Nov 15; 92(10):2639-47.
View in: PubMed

Ambrosone CB, Sweeney C, Coles BF, Thompson PA, McClure GY, Korourian S, Fares MY, Stone A, Kadlubar FF, Hutchins LF. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 2001 Oct 01; 61(19):7130-5.
View in: PubMed

Coles B, Nowell SA, MacLeod SL, Sweeney C, Lang NP, Kadlubar FF. The role of human glutathione S-transferases (hGSTs) in the detoxification of the food-derived carcinogen metabolite N-acetoxy-PhIP, and the effect of a polymorphism in hGSTA1 on colorectal cancer risk. Mutat Res. 2001 Oct 01; 482(1-2):3-10.
View in: PubMed

Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep; 298(3):976-85.
View in: PubMed

Sweeney C. History of testicular cancer chemotherapy: maximizing efficacy, minimizing toxicity. Semin Urol Oncol. 2001 Aug; 19(3):170-9.
View in: PubMed

Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry. 2001 Aug; 71(2):149-54.
View in: PubMed

Sweeney C, Bruera E. Research opportunities in palliative medicine. Tex Med. 2001 Aug; 97(8):64-8.
View in: PubMed

Sweeney C, Beattie-Palmer L, Palmer JL, Bruera E. Changing patterns of symptom control and palliative care paper presentations at the annual meeting of the American Society of Clinical Oncology. J Clin Oncol. 2001 Jul 15; 19(14):3438-9.
View in: PubMed

Bruera E, Sweeney C. The development of palliative care at the University of Texas M.D. Anderson Cancer Center. Support Care Cancer. 2001 Jul; 9(5):330-4.
View in: PubMed

Bruera E, Sweeney C, Calder K, Palmer L, Benisch-Tolley S. Patient preferences versus physician perceptions of treatment decisions in cancer care. J Clin Oncol. 2001 Jun 01; 19(11):2883-5.
View in: PubMed

Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001 Apr 15; 61(8):3369-72.
View in: PubMed

Sweeney C, Fambrough D, Huard C, Diamonti AJ, Lander ES, Cantley LC, Carraway KL. Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J Biol Chem. 2001 Jun 22; 276(25):22685-98.
View in: PubMed

Carraway KL, Sweeney C. Localization and modulation of ErbB receptor tyrosine kinases. Curr Opin Cell Biol. 2001 Apr; 13(2):125-30.
View in: PubMed

Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001 Feb 15; 19(4):1195-206.
View in: PubMed

Sweeney C, Carraway KL. Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene. 2000 Nov 20; 19(49):5568-73.
View in: PubMed

Bruera E, Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncol. 2000 Nov; 1:138-47.
View in: PubMed

Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA, Korourian S, Hutchins LF, Kadlubar FF, Ambrosone CB. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res. 2000 Oct 15; 60(20):5621-4.
View in: PubMed

Sweeney C, Lai C, Riese DJ, Diamonti AJ, Cantley LC, Carraway KL. Ligand discrimination in signaling through an ErbB4 receptor homodimer. J Biol Chem. 2000 Jun 30; 275(26):19803-7.
View in: PubMed

Hermans BP, Sweeney CJ, Foster RS, Einhorn LE, Donohue JP. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol. 2000 Jun; 163(6):1721-4.
View in: PubMed

Sweeney CJ, Sandler AB. Chemotherapy in non-small cell lung cancer. Invest New Drugs. 2000 May; 18(2):157-86.
View in: PubMed

Sweeney C, Farrow DC. Differential survival related to smoking among patients with renal cell carcinoma. Epidemiology. 2000 May; 11(3):344-6.
View in: PubMed

Sweeney C, Farrow DC, Schwartz SM, Eaton DL, Checkoway H, Vaughan TL. Glutathione S-transferase M1, T1, and P1 polymorphisms as risk factors for renal cell carcinoma: a case-control study. Cancer Epidemiol Biomarkers Prev. 2000 Apr; 9(4):449-54.
View in: PubMed

Farrow DC, Vaughan TL, Sweeney C, Gammon MD, Chow WH, Risch HA, Stanford JL, Hansten PD, Mayne ST, Schoenberg JB, Rotterdam H, Ahsan H, West AB, Dubrow R, Fraumeni JF, Blot WJ. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control. 2000 Mar; 11(3):231-8.
View in: PubMed

Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000 Feb; 21(2):139-46.
View in: PubMed

Sweeney CJ, Hermans BP, Heilman DK, Foster RS, Donohue JP, Einhorn LH. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer. J Clin Oncol. 2000 Jan; 18(2):358-62.
View in: PubMed

Yip-Schneider MT, Lin A, Barnard D, Sweeney CJ, Marshall MS. Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. Int J Oncol. 1999 Aug; 15(2):271-9.
View in: PubMed

Sweeney CJ, Williams SD, Finch DE, Bihrle R, Foster RS, Collins M, Fox S, Roth BJ. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer. 1999 Aug 01; 86(3):514-8.
View in: PubMed

Michael H, Hull MT, Foster RS, Sweeney CJ, Ulbright TM. Nephroblastoma-like tumors in patients with testicular germ cell tumors. Am J Surg Pathol. 1998 Sep; 22(9):1107-14.
View in: PubMed

Sweeney CJ, Sandler AB. Treatment of advanced (stages III and IV) non-small-cell lung cancer. Curr Probl Cancer. 1998 Mar-Apr; 22(2):85-132.
View in: PubMed

Mason RM, Sweeney C. The relationship between proteoglycan synthesis in Swarm chondrocytes and pathways of cellular energy and UDP-sugar metabolism. Carbohydr Res. 1994 Mar 04; 255:255-70.
View in: PubMed

Sage MR, Brophy BP, Sweeney C, Phipps S, Perrett LV, Sandhu A, Albertyn LE. Cavernous haemangiomas (angiomas) of the brain: clinically significant lesions. Australas Radiol. 1993 May; 37(2):147-55.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Top